A Phase I Study of TNB-383B in People with Recurrent or Persistent Multiple Myeloma

Full Title

A Multicenter, Phase 1, Open-label, Dose-Escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

Purpose

The purpose of this study is to assess the safety of the investigational drug TNB-383B in people with multiple myeloma that has come back or continued to grow despite treatment. TNB-383B is called a “bispecific antibody.” It works against cancer by targeting a protein on cancer cells, and it also helps the immune system find and attack multiple myeloma cells. TNB-383B is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

• Participants must have multiple myeloma that has come back or continued to grow after three or more prior regimens of treatment.
• At least 3 weeks must pass between the completion of previous therapies and receipt of TNB-383B.
• Patients must be able to walk and do routine activities for more than half of their normal waking hours.
• This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Neha Korde at 646-608-3708.